Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018

Date: July 17, 2018
Pages: 601
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NB7EE021D24EN
Leaflet:

Download PDF Leaflet

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 34, 29, 7, 106 and 37 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Non-Alcoholic Steatohepatitis (NASH) - Overview
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment
Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development
Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products
Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.7), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.8), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Products under Development by Companies, H2 2018 (Contd.7), H2 2018
Products under Development by Companies, H2 2018 (Contd.8), H2 2018
Products under Development by Companies, H2 2018 (Contd.9), H2 2018
Products under Development by Companies, H2 2018 (Contd.10), H2 2018
Products under Development by Companies, H2 2018 (Contd.11), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.2), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.3), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.4), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.2), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.3), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.4), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abide Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Akcea Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aldeyra Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Plc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Araim Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ardelyx Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ascletis Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Assembly Biosciences Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AstraZeneca Plc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Baliopharm AG, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Betagenon AB, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BioElectron Technology Corp, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bird Rock Bio Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BLR Bio LLC, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bristol-Myers Squibb Co, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cadila Healthcare Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Can-Fite BioPharma Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cardax Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Carmot Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Catabasis Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Celgene Corp, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cerenis Therapeutics Holding SA, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ChemoCentryx Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CJ HealthCare Corp, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CohBar Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ConSynance Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CymaBay Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Debiopharm International SA, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dicerna Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by DURECT Corp, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Eli Lilly and Co, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enanta Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enyo Pharma SA, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Esperion Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Exicure Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Forma Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galectin Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galecto Biotech AB, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galmed Pharmaceuticals Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gemphire Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Genfit SA, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GenKyoTex SA, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gilead Sciences Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GRI Bio Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by HemoShear Therapeutics, LLC, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by IB Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by iCo Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Immupharma Plc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Immuron Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Integral Molecular Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Intercept Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Inventiva, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kowa Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Madrigal Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by MallInckrodt Plc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by MedImmune LLC, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Merck & Co Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Metabolys SAS, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Metacrine Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Mina Therapeutics Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Naia Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NeuroVive Pharmaceutical AB, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nippon Chemiphar Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NorthSea Therapeutics BV, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novartis AG, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NovaTarg Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novo Nordisk AS, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nuevolution AB, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NuSirt Biopharma Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Oramed Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pfizer Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pharmaxis Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Poxel SA, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Promethera Biosciences SA, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ProMetic Life Sciences Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Protalix BioTherapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Redx Pharma Plc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Regulus Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by reMYND NV, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ritter Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Saje Pharma LLC, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sancilio & Company Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sanofi, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ScandiCure AB, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Second Genome Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Seres Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Shire Plc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sprint Bioscience AB, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Synlogic Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Terns Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Tiziana Life Sciences Plc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TRACON Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vascular Biogenics Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Verlyx Pharma Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Viking Therapeutics Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Visionary Pharmaceuticals Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by WAVE Life Sciences Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zafgen Inc, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zebra Discovery Ltd, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2018 (Contd.1), H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2018 (Contd.2), H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2018 (Contd.3), H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

COMPANIES MENTIONED

Abide Therapeutics Inc
AdAlta Ltd
Akcea Therapeutics Inc
Albireo Pharma Inc
Aldeyra Therapeutics Inc
Allergan Plc
Araim Pharmaceuticals Inc
Arcturus Therapeutics Ltd
Ardelyx Inc
Ascletis Inc
Assembly Biosciences Inc
AstraZeneca Plc
Baliopharm AG
Betagenon AB
BioElectron Technology Corp
Bird Rock Bio Inc
BLR Bio LLC
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Cardax Inc
Carmot Therapeutics Inc
Catabasis Pharmaceuticals Inc
Celgene Corp
Cerenis Therapeutics Holding SA
ChemoCentryx Inc
CJ HealthCare Corp
CohBar Inc
ConSynance Therapeutics Inc
CymaBay Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Dicerna Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dong-A Socio Holdings Co Ltd
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperion Therapeutics Inc
Exicure Inc
Forma Therapeutics Inc
Galectin Therapeutics Inc
Galecto Biotech AB
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GRI Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoShear Therapeutics, LLC
IB Pharmaceuticals Inc
iCo Therapeutics Inc
Immupharma Plc
Immuron Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Inventiva
Ionis Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
Madrigal Pharmaceuticals Inc
MallInckrodt Plc
MedImmune LLC
Merck & Co Inc
Metabolys SAS
Metacrine Inc
Mina Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
Naia Ltd
NeuroVive Pharmaceutical AB
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
NorthSea Therapeutics BV
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Nuevolution AB
NuSirt Biopharma Inc
Oramed Pharmaceuticals Inc
Pfizer Inc
Pharmaxis Ltd
Poxel SA
Promethera Biosciences SA
ProMetic Life Sciences Inc
Protalix BioTherapeutics Inc
Redx Pharma Plc
Regulus Therapeutics Inc
reMYND NV
Ritter Pharmaceuticals Inc
Saje Pharma LLC
Sancilio & Company Inc
Sanofi
ScandiCure AB
Second Genome Inc
Seres Therapeutics Inc
Shire Plc
Sprint Bioscience AB
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Terns Pharmaceuticals Inc
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
Vascular Biogenics Ltd
Verlyx Pharma Inc
Viking Therapeutics Inc
Visionary Pharmaceuticals Inc
WAVE Life Sciences Ltd
Zafgen Inc
Zebra Discovery Ltd
Skip to top


Alcohol Addiction - Pipeline Review, H2 2018 US$ 2,000.00 Jul, 2018 · 151 pages

Ask Your Question

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: